DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Crystal Gateway Marriott

2026年9月23日 (水) 午前 8:15 - 2026年9月25日 (金) 午後 12:45

1700 Richmond Highway, Arlington, VA 22202, USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Session 11: Grand Q&A Panel

Session Chair(s)

René  Thürmer

René Thürmer

Deputy Head of the Unit Pharmaceutical Biotechnology BfArM, Federal Institute for Drugs and Medical Devices, Germany

This session will allow open discussion between the audience and an esteemed panel of experts to ask any remaining questions. Please note: due to the high volume of questions, not all will be answered live at the conference

Speaker(s)

Hobart  Rogers, PharmD, PhD

Speaker

Hobart Rogers, PharmD, PhD

Pharmacologist, CDER, FDA, United States

Andrew  Slugg, MBA, MS

Speaker

Andrew Slugg, MBA, MS

Senior Vice President, Global Head of Regulatory Sciences, Alnylam Pharmaceuticals, United States

Jennifer  Sisler, PhD

Speaker

Jennifer Sisler, PhD

Director, Eli Lilly and Company, United States

Xuan  Chi, DRSc, MD, PhD

Speaker

Xuan Chi, DRSc, MD, PhD

Supervisory Pharmacologist, CDER, FDA, United States

Lubomir  Nechev, PhD

Speaker

Lubomir Nechev, PhD

Chief CMC Officer, Alnylam Pharmaceuticals, United States

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。